Patents by Inventor Yoshihisa Kuwana
Yoshihisa Kuwana has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180221377Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.Type: ApplicationFiled: March 1, 2018Publication date: August 9, 2018Inventors: Hiroshi Kase, Akihisa Mori, Yutaka Waki, Yutaka Ohsawa, Akira Karasawa, Yoshihisa Kuwana
-
Publication number: 20170196872Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.Type: ApplicationFiled: January 24, 2017Publication date: July 13, 2017Inventors: Hiroshi Kase, Akihisa Mori, Yutaka Waki, Yutaka Ohsawa, Akira Karasawa, Yoshihisa Kuwana
-
Publication number: 20140249166Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.Type: ApplicationFiled: March 27, 2014Publication date: September 4, 2014Applicant: Kyowa Hakko Kirin Co., Ltd.Inventors: Hiroshi Kase, Akihisa Mori, Yutaka Waki, Yutaka Ohsawa, Akira Karasawa, Yoshihisa Kuwana
-
Publication number: 20120122897Abstract: Methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof and methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. Also, methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA with an effective amount of one or more adenosine A2A receptor antagonists, optionally with a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.Type: ApplicationFiled: November 16, 2011Publication date: May 17, 2012Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Hiroshi Kase, Akihisa Mori, Yutaka Waki, Yutaka Ohsawa, Akira Karasawa, Yoshihisa Kuwana
-
Patent number: 7727994Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.Type: GrantFiled: January 6, 2006Date of Patent: June 1, 2010Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Hiroshi Kase, Akihisa Mori, Yutaka Waki, Yutaka Ohsawa, Akira Karasawa, Yoshihisa Kuwana
-
Patent number: 7727993Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.Type: GrantFiled: January 6, 2006Date of Patent: June 1, 2010Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Hiroshi Kase, Akihisa Mori, Yutaka Waki, Yutaka Ohsawa, Akira Karasawa, Yoshihisa Kuwana
-
Publication number: 20080207649Abstract: The present invention relates to a method of treating various neurodegenerative disorders, in which a xanthine derivative represented by formula (I): or a pharmaceutically acceptable salt thereof, as an active ingredient, is administered.Type: ApplicationFiled: April 30, 2008Publication date: August 28, 2008Inventors: Junichi SHIMADA, Masako Kurokawa, Ken Ikeda, Fumio Suzuki, Yoshihisa Kuwana
-
Publication number: 20070073043Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.Type: ApplicationFiled: September 19, 2005Publication date: March 29, 2007Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Publication number: 20060258688Abstract: The present invention relates to a method of treating various neurodegenerative disorders, in which a xanthine derivative represented by formula (I): or a pharmaceutically acceptable salt thereof, as an active ingredient, is administered.Type: ApplicationFiled: July 19, 2006Publication date: November 16, 2006Inventors: Junichi Shimada, Masako Kurokawa, Ken Ikeda, Fumio Suzuki, Yoshihisa Kuwana
-
Patent number: 7115614Abstract: The present invention relates to a method of treating brain ischemia in which a xanthine derivative represented by formula (I): or a pharmaceutically acceptable salt thereof, as an active ingredient, is administered.Type: GrantFiled: October 27, 2003Date of Patent: October 3, 2006Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Junichi Shimada, Masako Kurokawa, Ken Ikeda, Fumio Suzuki, Yoshihisa Kuwana
-
Publication number: 20060178379Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.Type: ApplicationFiled: January 6, 2006Publication date: August 10, 2006Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Hiroshi Kase, Akihisa Mori, Yutaka Waki, Yutaka Ohsawa, Akira Karasawa, Yoshihisa Kuwana
-
Publication number: 20060148827Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.Type: ApplicationFiled: January 6, 2006Publication date: July 6, 2006Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Hiroshi Kase, Akihisa Mori, Yutaka Waki, Yutaka Ohsawa, Akira Karasawa, Yoshihisa Kuwana
-
Patent number: 7045129Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.Type: GrantFiled: June 12, 2002Date of Patent: May 16, 2006Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Publication number: 20060057139Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.Type: ApplicationFiled: October 25, 2005Publication date: March 16, 2006Applicant: KYOWA HAKKO KOGYO CO., LTDInventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Publication number: 20060058512Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.Type: ApplicationFiled: September 19, 2005Publication date: March 16, 2006Applicant: KYOWA HAKKO KOGYO CO., LTDInventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Publication number: 20060058320Abstract: The present invention provides [1,2,4]triazolo[1,5-c]pyrimidine derivatives or pharmaceutically acceptable salts thereof which have adenosine A2A receptor antagonism and are useful for treating and/or preventing a disease induced by hyperactivity of an adenosine A2A receptor, the derivatives being represented by formula (I): (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R2 represents a hydrogen atom, halogen, lower alkyl, lower alkanoyl, aroyl, substituted or unsubstituted aryl, or a substituted or unsubstituted aromatic heterocyclic group; R3 represents lower alkyl, lower cycloalkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aryl, or a substituted or unsubstituted aromatic heterocyclic group; and Q represents a hydrogen atom or 3,4-dimethoxybenzyl).Type: ApplicationFiled: September 24, 2003Publication date: March 16, 2006Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kyoichiro Iida, Takamasa Sugita, Shizuo Shiozaki, Tomoyuki Kanda, Yoshihisa Kuwana, Junichi Shimada
-
Patent number: 6965024Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of said humanized chimera antibody, are disclosed.Type: GrantFiled: October 8, 2002Date of Patent: November 15, 2005Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Patent number: 6872392Abstract: Chimeric human antibody expression vectors are constructed by inserting the heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM2 respectively into an expression vector which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured to produce a chimeric human antibody reacting with the ganglioside GM2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but show a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.Type: GrantFiled: July 16, 2002Date of Patent: March 29, 2005Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kazuyasu Nakamura, Masamichi Koike, Kenya Shitara, Nobuo Hanai, Yoshihisa Kuwana, Mamoru Hasegawa
-
Publication number: 20040229888Abstract: The present invention relates to a therapeutic agent for neurodegenerative disorders, comprising a xanthine derivative represented by formula (I): 1Type: ApplicationFiled: October 27, 2003Publication date: November 18, 2004Inventors: Junichi Shimada, Masako Kurokawa, Ken Ikeda, Fumio Suzuki, Yoshihisa Kuwana
-
Publication number: 20040198753Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.Type: ApplicationFiled: January 28, 2003Publication date: October 7, 2004Inventors: Hiroshi Kase, Akihisa Mori, Yutaka Waki, Yutaka Ohsawa, Akira Karasawa, Yoshihisa Kuwana